1. In vitro evaluation of pathogen inactivated platelet quality: An 8 year experience of routine use in Galicia, Spain
- Author
-
Almudena Díaz Pereira, Carina Arcas Otero, Azucena Castrillo Fernández, Maria Adelantado Pérez, and Marion C. Lanteri
- Subjects
Blood Platelets ,Amotosalen ,Time Factors ,medicina transfusional ,eliminación de componentes sanguíneos ,activación plaquetaria ,Control de calidad de plaquetas ,030204 cardiovascular system & hematology ,Shelf life ,Andrology ,03 medical and health sciences ,plaquetas ,0302 clinical medicine ,Producción de plaquetas ,medicine ,Humans ,Distribution (pharmacology) ,Platelet ,Platelet activation ,Adverse effect ,Transfusion Medicine ,Chemistry ,Hematology ,Metabolism ,Platelet Activation ,humanities ,Red blood cell ,medicine.anatomical_structure ,Spain ,Blood Component Removal ,030215 immunology - Abstract
BACKGROUND: Platelet concentrates (PCs) treated by the pathogen inactivation technology (PI) using amotosalen and UVA illumination (PI-PCs) can be manufactured in additive solutions (PAS-III and PAS-IIIM) or in 100% Plasma. Quality control (QC) is an integral part of the production. We capitalized on our ongoing QC program to capture 8 years-worth of data on parameters related to the quality of 116,214 PI-PCs produced under different manufacturing methods. MATERIALS AND METHODS: Selected in vitro parameters of metabolism, activation, and storage were analyzed for the different manufacturing periods to compare PI-PCs versus conventional PCs (C-PCs) resuspended in different PAS. RESULTS AND DISCUSSION: All BC-PCs met quality standards for pH and dose and residual leucocytes. As expected, storage time correlated with increased lactate, LDH, Annexin V, CD62, sCD40 L levels and decreased glucose and pH. With PAS-IIIM, higher levels of glucose were observed toward the end of shelf life (p
- Published
- 2019
- Full Text
- View/download PDF